Literature DB >> 16000848

The role of cytokeratin 19 in the differential diagnosis of true papillary carcinoma of thyroid and papillary carcinoma-like changes in Graves' disease.

Suna Erkiliç1, N Emrah Koçer.   

Abstract

Graves' disease is an autoimmune disease predominantly seen in females. All types of thyroid cancers may co-exist with Graves' disease but papillary carcinoma is the most frequent. Vesicular nuclei, nuclear grooves, and papillary formations that may be seen in Graves' disease may lead the pathologist to an overdiagnosis of papillary carcinoma. The differential diagnosis between a true papillary carcinoma and foci mimicking papillary carcinoma in Graves' disease may be challenging by light microscopic features only. This study is designed to determine whether CK19 is effective in the discrimination between the true papillary carcinoma of thyroid and foci resembling papillary carcinoma in Graves' disease. Twenty-five cases with papillary carcinoma and 25 cases with Graves' disease containing foci resembling papillary carcinoma were included in the study. All 25 cases with papillary carcinoma stained positive with CK19, whereas only six of 25 cases with Graves' disease showed weak staining, and the remaining 19 cases were completely negative. It is known that CK19 may show faint staining in benign thyroid lesions such as adenomas. Staining pattern with CK19 together with histopathological findings may be helpful in the differential diagnosis between foci mimicking papillary carcinoma and true papillary carcinoma in Graves' disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16000848     DOI: 10.1385/ep:16:1:063

Source DB:  PubMed          Journal:  Endocr Pathol        ISSN: 1046-3976            Impact factor:   3.943


  11 in total

1.  Differential expression of cytokeratins in follicular variant of papillary carcinoma: an immunohistochemical study and its diagnostic utility.

Authors:  Z W Baloch; S Abraham; S Roberts; V A LiVolsi
Journal:  Hum Pathol       Date:  1999-10       Impact factor: 3.466

2.  Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma: a note of caution.

Authors:  S Sahoo; S A Hoda; J Rosai; R A DeLellis
Journal:  Am J Clin Pathol       Date:  2001-11       Impact factor: 2.493

3.  Utility of immunohistochemistry in the evaluation of necrotic thyroid tumors.

Authors:  A R Judkins; S A Roberts; V A Livolsi
Journal:  Hum Pathol       Date:  1999-11       Impact factor: 3.466

4.  Expression of keratin 19 distinguishes papillary thyroid carcinoma from follicular carcinomas and follicular thyroid adenoma.

Authors:  L J Schelfhout; G N Van Muijen; G J Fleuren
Journal:  Am J Clin Pathol       Date:  1989-11       Impact factor: 2.493

5.  Distribution of keratins in normal endothelial cells and a spectrum of vascular tumors: implications in tumor diagnosis.

Authors:  M Miettinen; J F Fetsch
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

6.  [Cytokeratin expression of benign and malignant epithelial thyroid gland tumors. An immunohistologic study of 154 neoplasms using 8 different monoclonal cytokeratin antibodies].

Authors:  S Schröder; A Wodzynski; B Padberg
Journal:  Pathologe       Date:  1996-11       Impact factor: 1.011

7.  Variable expression of keratins and nearly uniform lack of thyroid transcription factor 1 in thyroid anaplastic carcinoma.

Authors:  M Miettinen; K O Franssila
Journal:  Hum Pathol       Date:  2000-09       Impact factor: 3.466

8.  Diagnostic utility of cytokeratin 19 expression in multinodular goiter with papillary areas and papillary carcinoma of thyroid.

Authors:  Suna Erkiliç; Abdullah Aydin; N Emrah Koçer
Journal:  Endocr Pathol       Date:  2002       Impact factor: 3.943

9.  Distinction between papillary thyroid hyperplasia and papillary thyroid carcinoma by immunohistochemical staining for cytokeratin 19, galectin-3, and HBME-1.

Authors:  Mary B Casey; Christine M Lohse; Ricardo V Lloyd
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

10.  [Hyperthyroidism and cancer of the thyroid].

Authors:  R Daou
Journal:  Chirurgie       Date:  1998-12
View more
  2 in total

1.  HBME1 and CK19 expression in non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) vs other follicular patterned thyroid lesions.

Authors:  Qandeel Sadiq; Radhika Sekhri; Daniel T Dibaba; Qi Zhao; Shweta Agarwal
Journal:  World J Surg Oncol       Date:  2021-05-08       Impact factor: 2.754

2.  Differential expression of galectin-3, CK19, HBME1, and Ret oncoprotein in the diagnosis of thyroid neoplasms by fine needle aspiration biopsy.

Authors:  Husain A Saleh; Jining Feng; Farah Tabassum; Opada Al-Zohaili; Muji Husain; Tamara Giorgadze
Journal:  Cytojournal       Date:  2009-09-18       Impact factor: 2.091

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.